SimAbs secures €1 million investment for advanced antibody production
SimAbs announces a successful capital raise of 1 million euro, marking a significant milestone in the company's journey since its inception in 2019. This funding, primarily sourced from a consortium of renowned entrepreneurs and business angels affiliated with BAN Vlaanderen, is earmarked to facilitate the next phase of the company's growth.
SimAbs' groundbreaking technology is centered on continuous manufacturing, offering unparalleled advantages in cost-effectiveness, accelerated time to market, and enhanced quality. This fresh injection of funds will be channeled towards establishing a GMP facility, paving the way for the manufacturing of antibodies tailored for human applications.
Koen Dierckx, CEO of SimAbs, expressed his enthusiasm, stating, "We are immensely proud to have garnered the support of such a distinguished group of investors. This collaboration brings together the expertise of business angels from BAN Vlaanderen and several eminent Flemish entrepreneurs. A significant portion of this funding round was contributed by ABN Cleanroom, spearheaded by Jo Nelissen and Rosaline Wijnen. With Jo also being a recipient of the 'Young Entrepreneur of the Year' accolade, we are confident in the robust foundation we've established for SimAbs' future endeavors."
